Fzata, Inc. is a Maryland biotechnology company founded by scientists whose research focuses on C. difficile infection and the gut’s immune response. The near-clinical-stage company develops oral biologic medicines for gastrointestinal and immune-related disease, using its BioPYM platform to deliver treatments directly in the gut. Its work has attracted more than $24 million in non-dilutive NIH funding.
2024 Innovation Celebration Winner – Biotechnology
certification
2017 Maryland Incubator Company of the Year, Best Life Sciences Company
certification
2022 Mid-Atlantic Innovation Winner for Biotechnology
certification
NuBiyotaFounded in 2013, Guelph-based NuBiyota develops microbiome therapeutics designed to restore gut balance, using multi-strain microbial compositions delivered as drug products. The company’s Microbial Ecosystem Therapeutics platform grew from University of Guelph research led by co-founder Dr. Emma Allen-Vercoe and supports four clinical-stage candidates. NuBiyota conducts research in Guelph and operates a GMP manufacturing hub in Pearl River, New York, with a strategic collaboration with Takeda for gastrointestinal indications.PEARL RIVER, NY
Rise Therapeutics, LLCRockville-based Rise Therapeutics develops oral immunotherapies that use synthetic biology to target dendritic cells and recalibrate immune responses in autoimmune disease and cancer. The clinical-stage company pairs its proprietary oral delivery platform with in-house clinical GMP manufacturing, taking candidates from discovery through human clinical validation. Its pipeline includes oral programs for ulcerative colitis, rheumatoid arthritis, and cancer.POTOMAC, MD
BioFactura, IncFounded in Frederick in 2004, BioFactura develops and manufactures biosimilars, biodefense medical countermeasures, and other biologic medicines using its patented StableFast biomanufacturing platform. The clinical-stage company has advanced programs for a smallpox therapeutic and a proposed ustekinumab biosimilar, while its Capitol Biologics division provides development and early-phase clinical manufacturing support to emerging biotech firms and government agencies.FREDERICK, MD
Therapyx IncPrivately held and co-founded by immunologists Nejat Egilmez and Richard Bankert, Therapyx Inc. is a Buffalo biotechnology start-up developing immune-based medicines. The company is known for its ExStaM platform, which uses microparticles to deliver protein therapeutics locally and over time for serious diseases.BUFFALO, NY